Mauro Nanni

1.4k total citations
43 papers, 804 citations indexed

About

Mauro Nanni is a scholar working on Genetics, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Mauro Nanni has authored 43 papers receiving a total of 804 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Genetics, 30 papers in Hematology and 11 papers in Pathology and Forensic Medicine. Recurrent topics in Mauro Nanni's work include Chronic Lymphocytic Leukemia Research (23 papers), Chronic Myeloid Leukemia Treatments (18 papers) and Acute Myeloid Leukemia Research (17 papers). Mauro Nanni is often cited by papers focused on Chronic Lymphocytic Leukemia Research (23 papers), Chronic Myeloid Leukemia Treatments (18 papers) and Acute Myeloid Leukemia Research (17 papers). Mauro Nanni collaborates with scholars based in Italy, United States and Sweden. Mauro Nanni's co-authors include Giuliana Alimena, Daniela Diverio, Francesco Lo‐Coco, Marco Mancini, Giuseppe Cimino, Roberta Gastaldi, Clara Nervi, Francesco Fazi, Lorena Travaglini and Massimo Breccia and has published in prestigious journals such as Science, Blood and Cancer.

In The Last Decade

Mauro Nanni

41 papers receiving 789 citations

Peers

Countries citing papers authored by Mauro Nanni

Since Specialization

Citations

This map shows the geographic impact of Mauro Nanni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mauro Nanni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mauro Nanni more than expected).

Fields of papers citing papers by Mauro Nanni

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mauro Nanni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mauro Nanni. The network helps show where Mauro Nanni may publish in the future.

Co-authorship network of co-authors of Mauro Nanni

This figure shows the co-authorship network connecting the top 25 collaborators of Mauro Nanni. A scholar is included among the top collaborators of Mauro Nanni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mauro Nanni. Mauro Nanni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Analysis of Single Nuclei in a Microfluidic Cytometer Towards Metaphase Enrichment 2025 ·Electrophoresis ·(unknown), Adele De Ninno, (unknown), Valentina Mussi, Mauro Nanni, Federica Caselli	0
2	Atypical Chronic Myeloid Leukemia in a Patient with Aplastic Anemia 2019 ·Acta Haematologica ·Michelina Santopietro, Maurizio Miano, Giovanna Palumbo, Kejian Zhang, (unknown), Sabina Chiaretti, Nadia Peragine, Mauro Nanni, Daniela Diverio, Francesca Mancini, Anna Maria Testi, Maria Luisa Moleti, Robin Foà, Fiorina Giona	2
3	Prognostic features of patients with myelodysplastic syndromes aged < 50 years: update of a single-institution experience 2012 ·Leukemia & lymphoma ·Massimo Breccia, (unknown), Giuseppina Loglisci, Michelina Santopietro, Adriano Salaroli, Alessandra Serrao, Roberto Latagliata, (unknown), Luigi Petrucci, Mauro Nanni, Giuliana Alimena	5
4	Complete Clearance of Ph+ Metaphases after 3 Months Is a Very Early Indicator of Good Response to Imatinib as Front-Line Treatment in Chronic Myelogenous Leukemia 2012 ·Acta Haematologica ·Roberto Latagliata, Alessandro Isidori, Massimo Breccia, Ida Carmosino, Federico Vozella, (unknown), (unknown), Sara Barulli, Giuseppina Loglisci, Michelina Santopietro, Vincenzo Federico, (unknown), Mauro Nanni, Marco Mancini, Giuseppe Visani, Giuliana Alimena	4
5	Behind the scenes of non‐nodal MCL: downmodulation of genes involved in actin cytoskeleton organization, cell projection, cell adhesion, tumour invasion, TP53 pathway and mutated status of immunoglobulin heavy chain genes 2011 ·British Journal of Haematology ·Ilaria Del Giudice, Monica Messina, Sabina Chiaretti, Simona Santangelo, Simona Tavolaro, Maria Stefania De Propris, Mauro Nanni, Edoardo Pescarmona, Francesca Mancini, Alessandro Pulsoni, Maurizio Martelli, Alice Di Rocco, (unknown), Francesca Paoloni, Francesca Romana Mauro, Antonio Cuneo, Anna Guarini, Robin Foà	17
6	5′-Azacitidine for therapy-related myelodysplastic syndromes after non-Hodgkin lymphoma treatment 2011 ·Leukemia Research ·Massimo Breccia, Adriano Salaroli, Giuseppina Loglisci, Maurizio Martelli, Gianna Maria D’Elia, Mauro Nanni, Francesca Romana Mauro, Giuliana Alimena	2
7	Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: Correlation with clinical outcome and gene expression profiling 2011 ·Genes Chromosomes and Cancer ·Sabina Chiaretti, Simona Tavolaro, M Marinelli, Monica Messina, Ilaria Del Giudice, Francesca Romana Mauro, Simona Santangelo, Alfonso Piciocchi, Nadia Peragine, (unknown), Nancy Patten, Emanuela M. Ghia, Isabella Torrente, Maria Stefania De Propris, Mauro Nanni, (unknown), Anna Guarini, Robin Foà	22
8	Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose 2009 ·Hematological Oncology ·Massimo Breccia, Laura Cannella, Caterina Stefanizzi, Roberto Latagliata, Mauro Nanni, Daniela Diverio, Michelina Santopietro, Vincenzo Federico, Giuliana Alimena	10
9	Nilotinib Can Override Dasatinib Resistance in Chronic Myeloid Leukemia Patients with Secondary Resistance to Imatinib First-Line Therapy 2007 ·Acta Haematologica ·Massimo Breccia, Laura Cannella, Mauro Nanni, Caterina Stefanizzi, Giuliana Alimena	8
10	Isolated thrombocytosis as first sign of chronic myeloid leukemia with e6a2 BCR/ABL fusion transcript, JAK2 negativity and complete response to imatinib 2007 ·Leukemia Research ·Massimo Breccia, Laura Cannella, Daniela Diverio, (unknown), Mauro Nanni, Caterina Stefanizzi, (unknown), Sergio Mecarocci, Giuliana Alimena	11
11	Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rate 2007 ·Leukemia Research ·Giuliana Alimena, Massimo Breccia, Luigia Luciano, (unknown), Daniela Diverio, Barbara Izzo, Biagio De Angelis, Marco Mancini, Roberto Latagliata, Ida Carmosino, Mauro Nanni, Marco Picardi, Bruno Rotoli, Franco Mandelli, Fabrizio Pane	9
12	Sequential Valproic Acid/All- trans Retinoic Acid Treatment Reprograms Differentiation in Refractory and High-Risk Acute Myeloid Leukemia 2006 ·Cancer Research ·Giuseppe Cimino, Francesco Lo‐Coco, Susanna Fenu, Lorena Travaglini, Erica Finolezzi, Marco Mancini, Mauro Nanni, (unknown), Francesco Fazi, Fabrizio Padula, Roberto Fiorini, Maria Antonietta Aloe Spiriti, Maria Concetta Petti, Adriano Venditti, Sergio Amadori, Franco Mandelli, Pier Giuseppe Pelicci, Clara Nervi	102
13	Sudden blast crisis in patients with Philadelphia chromosome‐positive chronic myeloid leukemia who achieved complete cytogenetic remission after imatinib therapy 2006 ·Cancer ·Giuliana Alimena, Massimo Breccia, Roberto Latagliata, Ida Carmosino, Eleonora Russo, Francesca Biondo, Daniela Diverio, Marco Mancini, Mauro Nanni, Franco Mandelli	18
14	Circulating myeloid dendritic cell directly isolated from patients with chronic myelogenous leukemia are functional and carry the bcr-abl translocation 2006 ·Leukemia Research ·Enrica Orsini, Elisabetta Calabrese, Roberta Maggio, (unknown), Mauro Nanni, (unknown), Agostino Tafuri, Anna Guarini, Robert Foà	11
15	Clinical features of prognostic significance in myelodysplastic patients with normal karyotype at high risk of transformation 2004 ·Leukemia Research ·Massimo Breccia, Marco Mancini, Mauro Nanni, Gianna Maria D’Elia, Ida Carmosino, Roberto Latagliata, Chiara Sarlo, Franco Mandelli, Giuliana Alimena	7
16	Extramedullary blast crisis occurring in a Philadelphia-positive chronic myeloid leukemia patient with major cytogenetic response to imatinib. 2004 ·PubMed ·Massimo Breccia, Mauro Nanni, Francesca Mancini, (unknown), Sergio Mecarocci, Giuliana Alimena	8
17	A new complex rearrangement involving the ETV6, LOC115548, and MN1 genes in a case of acute myeloid leukemia 2004 ·Genes Chromosomes and Cancer ·Elena Belloni, Maurizio Trubia, Marco Mancini, (unknown), Mauro Nanni, Idoya Lahortiga, Roberta Riccioni, Stefano Confalonieri, Francesco Lo‐Coco, Pier Paolo Di Fiore, Pier Giuseppe Pelicci	13
18	Combined cytogenetic, FISH and molecular analysis in acute promyelocytic leukaemia at diagnosis and in complete remission 1995 ·British Journal of Haematology ·Marco Mancini, Mauro Nanni, Michele Cedrone, Daniela Diverio, Giuseppe Avvisati, Roberta Riccioni, Maria Rosaria, (unknown), Susanna Fenu, Giuliana Alimena	31
19	Management of Chronic Myeloid Leukemia in Chronic Phase with Autologous Stem Cell Transplantation and Alpha-2 Interferon: Cytogenetic and Clinical Results 1993 ·Leukemia & lymphoma ·Giuliana Alimena, Giovanna Meloni, (unknown), (unknown), Francesco Lo‐Coco, Enrico Montefusco, Marco Mancini, Rita M. Pinto, Mauro Nanni, Michele Cedrone, Paolo de Fabritiis, F Mandelli	4
20	Tetraploid karyotype (92,XXYY) in two patients with acute lymphoblastic leukemia 1987 ·Cancer Genetics and Cytogenetics ·Sverre Heim, Giuliana Alimena, Rolf Billström, Daniela Diverio, Ulf Kristoffersson, Nils Mandahl, Mauro Nanni, Felix Mitelman	19

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact